Literature DB >> 15794642

Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein.

Christine M Palermo1, Claire A Westlake, Thomas A Gasiewicz.   

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor known to mediate the toxic effects of numerous environmental contaminants, including the polycyclic aromatic hydrocarbons (PAHs). Historically, binding of PAHs to the AhR and the events leading to the generation of DNA adducts have been associated with chemical carcinogenesis. Previous investigations have implicated green tea (GT) as affording protection against PAH-induced cancers in animal models. Investigations in our laboratory have demonstrated that the GT polyphenol epigallocatechin gallate (EGCG) is capable of antagonizing AhR-mediated gene transcription, implicating inhibition of AhR signaling as a potential chemopreventive mechanism. This line of investigation was directed at elucidating the molecular mechanism of this antagonism. Competitive binding assays strongly suggest that EGCG does not bind to the AhR ligand binding site, indicating this compound functions through a mechanism unlike that of typical AhR antagonists. Affinity chromatography experiments implicate an indirect mechanism of action involving direct binding of EGCG to the AhR chaperone protein, hsp90. This induces an AhR conformation capable of nuclear localization but incapable of binding DNA. These altered signaling events correlate with the formation of a complex with sedimentation characteristics different from those of the latent or ligand-activated AhR. These data implicate a model in which EGCG inhibits release of hsp90 from the AhR, stabilizing the complex in an intermediary state associated with XAP2. This is the first time EGCG has been demonstrated to directly bind hsp90 and the first indication that GT may exert its chemopreventive effects through an interaction with the common chaperone hsp90.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794642     DOI: 10.1021/bi047433p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  41 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

2.  Epigallocatechin-3-gallate regulates cell growth, cell cycle and phosphorylated nuclear factor-κB in human dermal fibroblasts.

Authors:  Dong-wook Han; Mi Hee Lee; Hak Hee Kim; Suong-hyu Hyon; Jong-chul Park
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

3.  Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.

Authors:  Hardik J Patel; Shanu Modi; Gabriela Chiosis; Tony Taldone
Journal:  Expert Opin Drug Discov       Date:  2011-05       Impact factor: 6.098

4.  Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor.

Authors:  Anuj Khandelwal; Jessica A Hall; Brian S J Blagg
Journal:  J Org Chem       Date:  2013-08-01       Impact factor: 4.354

Review 5.  Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.

Authors:  Gaurav Garg; Anuj Khandelwal; Brian S J Blagg
Journal:  Adv Cancer Res       Date:  2016-02-10       Impact factor: 6.242

6.  Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties.

Authors:  Orly Weinreb; Tamar Amit; Silvia Mandel; Moussa B H Youdim
Journal:  Genes Nutr       Date:  2009-09-10       Impact factor: 5.523

Review 7.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 8.  Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?

Authors:  Thomas Walle
Journal:  Semin Cancer Biol       Date:  2007-05-13       Impact factor: 15.707

Review 9.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 10.  Signal transduction and molecular targets of selected flavonoids.

Authors:  Ann M Bode; Zigang Dong
Journal:  Antioxid Redox Signal       Date:  2013-04-15       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.